Showing results (141-150 of 152) with videos related to
Sort By:
Pageof 16
JACC. Cardiovascular Interventions|July 23, 2011
Angiographic geometric changes of the lumen arterial wall after bioresorbable vascular scaffolds and metallic platform stents at 1-year follow-upJosep Gomez-Lara, Salvatore Brugaletta, Vasim Farooq, et al.JACC. Cardiovascular Interventions|March 26, 2013
The REMEDEE trial: a randomized comparison of a combination sirolimus-eluting endothelial progenitor cell capture stent with a paclitaxel-eluting stentMichael Haude, Stephen W L Lee, Stephen G Worthley, et al.International Journal of Cardiology|June 11, 2011
A randomized, controlled, multi-center trial comparing the safety and efficacy of zotarolimus-eluting and paclitaxel-eluting stents in de novo lesions in coronary arteries: final results of the ZoMaxx II trialWilliam A Gray, Alan C Yeung, Donald E Cutlip, et al.JACC. Cardiovascular Interventions|November 20, 2010
A comparison of the conformability of everolimus-eluting bioresorbable vascular scaffolds to metal platform coronary stentsJosep Gomez-Lara, Hector M Garcia-Garcia, Yoshinobu Onuma, et al.Eurointervention : Journal of Europcr in Collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology|April 27, 2011
Comparison between the first and second generation bioresorbable vascular scaffolds: a six month virtual histology studySalvatore Brugaletta, Hector M Garcia-Garcia, Roberto Diletti, et al.Circulation|September 1, 2020
Colchicine in Patients With Acute Coronary Syndrome: The Australian COPS Randomized Clinical TrialDavid C Tong, Stephen Quinn, Arthur Nasis, et al.Journal of the American College of Cardiology|July 9, 2011
6-month clinical outcomes following implantation of the bioresorbable everolimus-eluting vascular scaffold in vessels smaller or larger than 2.5 mmRoberto Diletti, Yoshinobu Onuma, Vasim Farooq, et al.Journal of the American College of Cardiology|October 7, 2004
Actinomycin-eluting stent for coronary revascularization: a randomized feasibility and safety study: the ACTION trialPatrick W Serruys, John A Ormiston, Georgios Sianos, et al.Eurointervention : Journal of Europcr in Collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology|May 1, 2013
The edge vascular response following implantation of the Absorb everolimus-eluting bioresorbable vascular scaffold and the XIENCE V metallic everolimus-eluting stent. First serial follow-up assessment at six months and two years: insights from the first-in-man ABSORB Cohort B and SPIRIT II trialsBill D Gogas, Christos V Bourantas, Hector M Garcia-Garcia, et al.JACC. Cardiovascular Interventions|June 23, 2012
Vascular response of the segments adjacent to the proximal and distal edges of the ABSORB everolimus-eluting bioresorbable vascular scaffold: 6-month and 1-year follow-up assessment: a virtual histology intravascular ultrasound study from the first-in-man ABSORB cohort B trialBill D Gogas, Patrick W Serruys, Roberto Diletti, et al.Pageof 16